Anthem · Semaglutide · US health-plan appeal rights

Semaglutide denied for failing step therapy by Anthem?

Q: How long do I have to appeal a Anthem Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem semaglutide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Semaglutide

## Anthem Step-Therapy Denials for Semaglutide: The Mechanic

Anthem's step-therapy denial on semaglutide (Ozempic, Wegovy, Rybelsus) is not a coverage exclusion — it is a sequencing requirement embedded in Anthem's commercial Clinical UM Guideline CG-DRUG-141 (Glucagon-Like Peptide-1 Receptor Agonists) and pharmacy policy administered through CarelonRx (Anthem's in-house PBM since January 2024, replacing IngenioRx branding). The denial letter typically cites failure to document a trial of metformin plus a preferred GLP-1 (often dulaglutide/Trulicity on Anthem's National Preferred Formulary) before semaglutide is approved. For T2DM members meeting CG-DRUG-141 criteria (HbA1c ≥6.5% within 12 months or established T2DM diagnosis), the step is the obstacle — not medical necessity.

## Why Most Step Denials Are Beatable

Three procedural levers collapse Anthem's step requirement:

1. ERISA §1185d step-therapy override (29 USC §1185d). Anthem must approve an override if the preferred agent (a) was previously tried and ineffective, (b) is expected to be ineffective based on clinical characteristics, (c) caused or is likely to cause adverse reaction, (d) is contraindicated, or (e) the patient is stable on the requested drug. Document any prior dulaglutide, liraglutide, or exenatide trial — even from a prior plan year — with pharmacy fill history (CarelonRx will pull this if asked). A single prior fill of Trulicity that did not achieve HbA1c target is sufficient.

2. CG-DRUG-141 internal carve-outs. The guideline itself permits direct-to-semaglutide approval when the prescriber attests to cardiovascular risk reduction indication (SUSTAIN-6 / ELIXA data — semaglutide carries an FDA CV indication that dulaglutide also carries but liraglutide does not). Frame the appeal around the SELECT trial CV outcome data; this shifts the request from "second-line glycemic control" to "guideline-directed CV risk reduction" under ADA Standards of Care §10.

3. State step-therapy override statutes. If the member is in NY, CA, CT, IL, OH, KY, IN, GA, MO, VA, NV, CO, or WI (all Anthem BCBS states with step-therapy override laws), the statutory clinical override timelines (typically 72 hours standard, 24 hours expedited) override Anthem's internal turnaround. File the override directly with CarelonRx clinical review, not the medical benefit team.

## Tactical Closing

Submit the appeal through the CarelonRx prior authorization portal, not the medical-side Anthem Availity channel — semaglutide for T2DM sits on the pharmacy benefit, and routing to the wrong reviewer adds 10–14 days. Attach: (1) HbA1c lab within 12 months, (2) pharmacy fill history showing any prior GLP-1 attempt, (3) prescriber attestation citing CG-DRUG-141 §III.B and ADA 2026 Standards. If denied at Level 1, demand the NQTL comparative analysis under 29 CFR §2590.712 showing how Anthem applies step requirements to comparable medical/surgical drugs — Anthem rarely produces this and the request alone often triggers reversal at Level 2.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Semaglutide

Other denial reasons for Anthem Semaglutide

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.